摘要
背景:L-四氢巴马汀(L-THP)是一种四氢原贝贝丁异喹啉生物碱。据报道含有异喹啉生物碱的植物化合物显示出对包括白血病的许多人类癌细胞系的潜在作用。我们假设L-THP是一种异喹啉生物碱,可能是一种抗急性淋巴细胞白血病(ALL)的潜在分子,在本研究中,我们评估L-THP对p53缺陷型白血病EU-4细胞系的体外作用。 方法:用于研究,使用p53无效白血病EU-4细胞并用LTHP处理。测定细胞的凋亡程度和存活力。通过western印迹和PCR研究完成凋亡相关蛋白如XIAP和MDM2的表达。 MDM2和XIAP的表达被小干扰RNA(siRNA)击倒。 结果:研究结果提示,L-THP引起EU-4细胞中XIAP介导的p53依赖性凋亡。随着剂量和时间的增加,L-THP的处理导致XIAP蛋白水平的降低。 L-THP通过抑制MDM2的表达,参与蛋白酶体依赖途径,导致XIAP蛋白表达下调。此外,实验的结果表明由于L-THP抑制XIAP或通过siRNA抑制白血病细胞对阿霉素的敏感性增加。 结论:研究结果证实L-THP通过抑制与蛋白酶体依赖性途径相关的MDM2和提高EU-4细胞对多柔比星的敏感性而下调XIAP蛋白而导致p53非依赖性细胞凋亡。 L-THP引起caspase活化并导致细胞凋亡,L-THP可能是一种新的特异性诱导p53无效白血病EU-4细胞凋亡的分子。
关键词: L-四氢巴马汀,异喹啉生物碱,白血病,EU-4细胞,XIAP,MDM2。
Current Molecular Medicine
Title:L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin
Volume: 17 Issue: 3
关键词: L-四氢巴马汀,异喹啉生物碱,白血病,EU-4细胞,XIAP,MDM2。
摘要: Background: L-Tetrahydropalmatine (L-THP) is a tetra-hydro protoberberine isoquinoline alkaloid. The phyto-compounds bearing isoquinoline alkaloids have been reported to show a potential effect against a number of human cancers cell lines including leukemia. We hypothesized that L-THP, being an isoquinoline alkaloid, could be a potential molecule against acute lymphoblastic leukemia (ALL), in this study, we evaluate L-THP against p53 deficient leukemia EU-4 cell lines in vitro.
Methods: For the study, p53 null leukemia EU-4 cells were used and treated with LTHP. The extent of apoptosis and viability of cells were determined. Expression of apoptosis related proteins such as XIAP and MDM2 was done by western blot and PCR studies. The expression of MDM2 and XIAP was knocked down by small interfering RNA (siRNA).
Results: Outcomes of the study suggested that L-THP caused p53-indipendent apoptosis mediated by XIAP in EU-4 cells. The treatment of L-THP caused a decrease in the levels of XIAP protein with increasing dose and time. L-THP caused down-regulation of XIAP protein via inhibiting the expression of MDM2 and involving proteasomedependent pathway. Also, the outcomes of experiments suggested increased sensitivity of leukemia cells towards doxorubicin due to the inhibition of XIAP by L-THP or by siRNA.
Conclusion: Findings of the study confirm that L-THP resulted in p53 independent apoptosis via down-regulating XIAP protein by inhibiting MDM2 associated with proteasome-dependent pathway and increased sensitivity of EU-4 cells against doxorubicin. L-THP caused activation of caspase and resulted in apoptosis, L-THP may be a novel molecule for inducing apoptosis specifically in p53 null leukemia EU-4 cells.
Export Options
About this article
Cite this article as:
L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170718170000
DOI https://dx.doi.org/10.2174/1566524017666170718170000 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Copper Homeostasis for the Developmental Progression of Intraerythrocytic Malarial Parasite
Current Topics in Medicinal Chemistry Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Current Drug Targets Effects of Intermittent Hypoxia and Light Aerobic Exercise on Circulating Stem Cells and Side Population, after Strenuous Eccentric Exercise in Trained Rats
Current Stem Cell Research & Therapy Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Genes Involved in Hereditary Hearing Impairment
Current Genomics Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets STIP Regulates ERK1/2 Signaling Pathway Involved in Interaction with PP1γ in Lymphoblastic Leukemia
Current Molecular Medicine Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Telomerase as a Cancer Target. Development of New Molecules
Current Topics in Medicinal Chemistry The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry Fluoroquinolones in Pediatrics
Current Drug Therapy Arsenic Trioxide in Hematological Malignancies: The New Discovery of an Ancient Drug
Current Pharmaceutical Biotechnology Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene
Letters in Drug Design & Discovery Epigenetics and Sjogren’s Syndrome
Current Pharmaceutical Biotechnology